Blueprint Medicines Stock Price

-3.79 (-5.21%)
Upgrade to Real-Time
Afterhours (Closed)
Volume 861,847
Bid Price 67.50
Ask Price 94.69
News -
Day High 73.86


52 Week Range


Day Low 68.80
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Blueprint Medicines Corporation BPMC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-3.79 -5.21% 68.91 20:00:00
Open Price Low Price High Price Close Price Prev Close
72.50 68.80 73.86 68.91 72.70
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
13,027 861,847 $ 70.43 $ 60,697,299 - 68.80 - 117.86
Last Trade Time Type Quantity Stock Price Currency
18:47:55 18 $ 68.86 USD


Draw Mode:

Blueprint Medicines Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 4.05B 58.84M 58.48M $ 793.73M $ 326.07M 5.16 -9.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -48.16k 1.70%

more financials information »

Blueprint Medicines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BPMC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week75.5278.3168.8074.82597,358-6.61-8.75%
1 Month110.74111.6868.8088.46570,388-41.83-37.77%
3 Months113.33117.8668.8098.59450,262-44.42-39.2%
6 Months85.29117.8668.8097.66408,757-16.38-19.21%
1 Year104.22117.8668.8094.65445,142-35.31-33.88%
3 Years69.57125.6143.2982.88502,248-0.66-0.95%
5 Years31.99125.6131.37575.81469,09736.92115.41%

Blueprint Medicines Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Your Recent History
Blueprint ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.